Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (181-190 of 224) with videos related to

Pageof 23
Sort By:
Science Translational Medicine|September 3, 2011
Identification of a disease-defining gene fusion in epithelioid hemangioendotheliomaMunir R Tanas, Andrea Sboner, Andre M Oliveira, et al.
Nature Communications|July 29, 2025
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancersRoman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki, et al.
The Journal of Pathology|January 8, 2014
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breastRachael Natrajan, Paul M Wilkerson, Caterina Marchiò, et al.
Oncogene|February 12, 2025
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinomaJames Stewart, Dragomir B Krastev, Rachel Brough, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
NPJ Breast Cancer|January 24, 2025
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypesFresia Pareja, Rohit Bhargava, Virginia F Borges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyJoo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
Nature Communications|July 15, 2025
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Cancer Research|April 23, 2021
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in CancerRoman M Chabanon, Daphné Morel, Thomas Eychenne, et al.
Nature Communications|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Pageof 23

Showing results (181-190 of 224) with videos related to

Sort By:
Pageof 23
Science Translational Medicine|September 3, 2011
Identification of a disease-defining gene fusion in epithelioid hemangioendotheliomaMunir R Tanas, Andrea Sboner, Andre M Oliveira, et al.
Nature Communications|July 29, 2025
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancersRoman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki, et al.
The Journal of Pathology|January 8, 2014
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breastRachael Natrajan, Paul M Wilkerson, Caterina Marchiò, et al.
Oncogene|February 12, 2025
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinomaJames Stewart, Dragomir B Krastev, Rachel Brough, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
NPJ Breast Cancer|January 24, 2025
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypesFresia Pareja, Rohit Bhargava, Virginia F Borges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyJoo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
Nature Communications|July 15, 2025
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Cancer Research|April 23, 2021
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in CancerRoman M Chabanon, Daphné Morel, Thomas Eychenne, et al.
Nature Communications|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Pageof 23